Beyond every binary is a more complex reality. And so it is with driver and passenger mutations. The separation of tumor mutations into drivers and passengers underpins much progress in the development of targeted therapies. By looking at passenger mutations more carefully, though, researchers at Yale University have shown that passenger mutations, too, played a role in how tumors progressed.
Parkinson’s disease (PD) is a neurodegenerative disorder. But not just. And it may not start that way.
There is increasing evidence that a-synuclein, the protein whose aggregates eventually destroy midbrain dopaminergic neurons in PD (and that are the cause of other diseases collectively known as the synucleinopathies), first aggregates “in enteric neurons, the neurons that control gastrointestinal function,” Collin Challis told BioWorld.
Keeping you up to date on recent developments in oncology, including: New approach to photothermal treatment beats biofilm problem; Origin story helps ovarian cancer prognosis; Sharper look yields new potential kinase target in ovarian cancer; Autophagy activation may prevent metastasis.
Keeping you up to date on recent developments in diagnostics, including: Creating a safer MRI contrast agent; Novel blood test for HPV-related head and neck cancer; More enhancers suggest more pathogenicity: study; Distinguishing real from backseat drivers.
The hormone prolactin is known for and named after its role in breastfeeding. But that is far from its only role. There are more than 300 identified functions of prolactin, which is present in both men and women, though women have higher levels, and extremely high levels late in pregnancy and during breastfeeding. Now, scientists at the University of Arizona have identified another function of prolactin signaling.
At this very early point in the emerging 2019-nCoV outbreak, knowledge about the virus is insufficient to predict what shape that outbreak will ultimately take.
The drug screens prompted by the SARS and MERS outbreaks have been useful for quickly identifying drug candidates. But in terms of their epidemiology, “SARS and MERS were different from this coronavirus,” Allison McGeer explained at a Feb. 3 webinar by Evercore ISI.
Keeping you up to date on recent developments in oncology, including: Study bolsters case for maximal resection for glioblastoma; CD47 knockout improves antitumor vaccine; Distinguishing real from backseat drivers; Protons come to American state of Alabama.
For depression, and other mental health disorders, the era of precision medicine has yet to arrive.
Symptoms are “very poorly reflective of the underlying biology,” Amit Etkin told BioWorld. Depression can manifest through multiple different symptoms that differ both between and within cultures.
Inclisiran’s inclusion on the 2020 Cortellis Drugs to Watch list is an example of target discovery possibilities hiding in plain sight – if companies and institutions are willing to put effort into increasing sample diversity in genomic research.